PH-797804
- Generic Name
- PH-797804
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19BrF2N2O3
- CAS Number
- 586379-66-0
- Unique Ingredient Identifier
- SI09I1V827
- Background
PH-797804 has been investigated for the treatment of Osteoarthritis.
- Associated Conditions
- -
- Associated Therapies
- -
PH-797804 Versus Placebo For The Treatment Of Neuropathic Pain Associated With Post-Herpetic Neuralgia
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 80
- Registration Number
- NCT00614705
- Locations
- 🇬🇧
Pfizer Investigational Site, Solihull, United Kingdom
A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 230
- Registration Number
- NCT00559910
- Locations
- 🇬🇧
Pfizer Investigational Site, Edinburgh, United Kingdom
An Oral p38 Inhibitor Investigating Safety, Efficacy, And PK In Subjects With Active Rheumatoid Arthritis
- First Posted Date
- 2006-10-02
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 305
- Registration Number
- NCT00383188
- Locations
- 🇧🇷
Hospital Heliópolis - PAM, São Paulo, SP, Brazil
🇨🇿NZZ Bormed, s.r.o., Ostrava - Trebovice, Czechia
🇮🇳Department of Rheumatology, CARE Hospital, Hyderabad, Andhra Pradesh, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath